Within wk of getting the initial study drug dose Rivaroxaban (ten mg
Inside wk of getting the very first study drug dose Rivaroxaban (ten mg day-to-day for 180 d) Placebo Initial confirmed VTE or VTE-related death NCT02555878 September 2015 JanuaryEfficacy and safety of rivaroxaban prophylaxis compared with placebo in ambulatory cancer individuals initiating systemic cancer therapy and at higher threat for venous thromboembolism Girls with pelvic malignancy undergoing surgical debulking Apixaban (two.5 mg twice everyday for 28 d postsurgery) Enoxaparin (40 mg every day for 28 d postsurgery)Randomized, doubleblind, placebocontrolled clinical trialThe safety of oral apixaban (Eliquis) vs subcutaneous enoxaparin (Lovenox) for thromboprophylaxis in females with suspected pelvic malignancy; a potential randomized open blinded end point (PROBE) designRandomized, singleblind, security studyIncidence of big bleedingNCTFebruaryMarchJournal of the American Heart AssociationContinuedTable 2. ContinuedTrialDesignPatient PopulationInterventionComparisonPrimary OutcomeClinical Trial RegistrationStudy Start out DateEstimated Completion DateEvidence Gaps of NOACsCONTEMPORARY REVIEWDOI: ten.1161/JAHA.117.Randomized, open-label, placebo-controlled clinical trial Placebo Composite of nonfatal VTE and VTE-related death main bleeding NCT02369653 AprilA phase III randomized, open label, multicenter study in the security and efficacy of apixaban for thromboembolism prevention vs no systemic anticoagulant prophylaxis during induction chemotherapy in kids with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoma (T or B cell) treated with pegylated L-asparaginase Sufferers with cancer, undergoing surgery Apixaban (2.five mg twice/ d) Placebo Initial episode of VTE NCT02048865 JanuaryChildren with new diagnosis of de novo acute IL-4 Protein Molecular Weight lymphocytic leukemia or lymphomas and planned induction chemotherapy using a corticosteroid, vincristine, and PEG Lasparaginase, with or with out daunorubicinApixaban (if 35 kg of 0.07 mg/kg twice per day 258 d, if 35 kg either two.five mg tablet twice a day or six.2 mL of your 0.4 mg/mL answer twice a day for 258 d)MayAronis and HylekApixaban for the prevention of venous thromboembolism in cancer individuals (AVERT) Existing or prior diagnosis of symptomatic multiple myeloma that will be starting or already getting immunomodulatory therapy (thalidomide, lenalidomide, or pornalidomide) Apixaban (two.5 mg orally twice every day for key prevention of VTE for a duration of 6 mo) Individuals with myeloma who’re treated with melphalan, prednisone, thalidomide, lenalidomide, or dexamethasone Apixaban (2.five mg twice/ d) PlaceboRandomized controlled, Betacellulin, Human double-blind placebocontrolled clinical trialJanuaryApixaban for key prevention of venous thromboembolism in sufferers with various myeloma getting immunomodulatory therapyRandomized, doubleblind, placebocontrolled clinical trialSymptomatic VTE Important and clinically relevant nonmajor bleedingNCTJanuaryDecemberJournal of your American Heart AssociationEvaluation from the use of apixaban in prevention of thromboembolic illness in sufferers with myeloma treated with iMiDs (MYELAXAT)Single-arm studyNoneVTE and VTE-related death Major and clinically relevant nonmajor bleedingNCTAprilJulyBW indicates physique weight; IU, International Unit; LMWH, low molecular weight heparin; NOACs, non itamin K oral anticoagulants; VTE, venous thromboembolic illness.Proof Gaps of NOACsAronis and HylekCONTEMPORARY REVIEWUntil the safety and efficacy of NOACs are compared with LMWH in randomized clinical trials of sufferers with can.
